BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260606
DTEND;VALUE=DATE:20260611
DTSTAMP:20260607T231421
CREATED:20260504T221047Z
LAST-MODIFIED:20260504T221047Z
UID:10330-1780704000-1781135999@thebiocalendar.com
SUMMARY:CYTO 2026
DESCRIPTION:CYTO 2026\, the 39th annual Congress of the International Society for the Advancement of Cytometry\, is the premier\, inclusive\, and international conference on the many facets of cytometry science and engineering. Guided by this year’s theme\, Cytometry: The Next Wave\, the meeting will showcase groundbreaking innovations and emerging directions shaping the field. Join us in West Palm Beach\, Florida—a destination celebrated for its year-round sunshine\, beautiful beaches\, vibrant arts scene\, and welcoming community. Home to a growing life sciences ecosystem\, anchored by leading biomedical research institutes\, innovative biotech companies\, and renowned medical centers\, this unique blend of community spirit and scientific innovation makes West Palm Beach the ideal setting for charting the next wave of cytometry at CYTO 2026.
URL:https://thebiocalendar.com/event/cyto-2026/
LOCATION:West Palm Beach\, West Palm Beach\, FL\, United States
CATEGORIES:Academic Research,Forum
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260609T110000
DTEND;TZID=America/Los_Angeles:20260609T120000
DTSTAMP:20260607T231421
CREATED:20260519T185932Z
LAST-MODIFIED:20260522T082449Z
UID:10469-1781002800-1781006400@thebiocalendar.com
SUMMARY:Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs
DESCRIPTION:In this webinar\, Lonza experts share insights from 70+ bispecific programs\, revealing the most common early‑stage risks across analytical development\, downstream purification\, and drug product formulation. You’ll learn where challenges typically emerge before IND\, how early decisions shape CMC readiness\, and when to rely on platform approaches versus molecule‑specific strategies to avoid costly delays. \nKey Learning Objectives:\n– Identify where development risks matter most before IND and what early stage challenges bispecific antibody programs most commonly run into\n– Understand how early analytical\, downstream\, and drug product formulation decisions can either accelerate progress or create downstream CMC and IND readiness challenges\n– Learn how Lonza balances speed and risk by knowing when platform approaches are sufficient and when molecule specific strategies are needed to avoid costly surprises
URL:https://thebiocalendar.com/event/cracking-complexity-learnings-from-70-bispecific-antibody-programs/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-09-26-Lonza-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260610T110000
DTEND;TZID=America/Los_Angeles:20260610T120000
DTSTAMP:20260607T231421
CREATED:20260519T191159Z
LAST-MODIFIED:20260522T082428Z
UID:10477-1781089200-1781092800@thebiocalendar.com
SUMMARY:Viral Safety Testing in Biologics: Detecting What Current Methods Miss
DESCRIPTION:This webinar breaks down how evolving expectations under ICH Q5A(R2) are reshaping viral detection strategies\, shifting the industry from targeted testing toward broader\, more sensitive approaches. Through real‑world examples\, you’ll learn where current methods fall short\, how newer technologies expand visibility\, and how teams can strengthen viral safety programs without disrupting development timelines or regulatory alignment. \nWatch the discussion to learn how to modernize viral safety testing and uncover what traditional methods may be missing.
URL:https://thebiocalendar.com/event/viral-safety-testing-in-biologics-detecting-what-current-methods-miss/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-10-26-Minaris-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260611T110000
DTEND;TZID=America/Los_Angeles:20260611T120000
DTSTAMP:20260607T231421
CREATED:20260520T185631Z
LAST-MODIFIED:20260522T082358Z
UID:10499-1781175600-1781179200@thebiocalendar.com
SUMMARY:Using Residual DNA Quantification Data to De-risk mAb Development
DESCRIPTION:IND submission is a critical milestone in mAb development — but analytical methods established at this stage must ultimately support validation\, tech transfer\, and evolving regulatory expectations. Among these\, residual host cell DNA quantitation assays play a central role in monitoring residual impurity levels\, supporting process performance\, and may help reduce downstream risks. \nThis webinar will position residual DNA quantitation not as an isolated assay\, but as a dataset that can be applied across downstream process intermediates to inform decision-making. Using data generated from protein-rich samples\, we will explore how assay sensitivity\, recovery\, and reproducibility perform under realistic manufacturing conditions\, including high IgG matrices. \nThrough practical examples\, attendees will see how residual DNA measurements can be used to compare purification performance across unit operations\, identify potential clearance risks early\, and support development of scalable\, validation-ready processes. The session will also highlight how sample composition and process conditions influence data interpretation\, reinforcing the importance of designing assays that remain robust as workflows evolve. \nLearning objectives: \n~ Evaluate how residual host cell DNA quantitation can be used to assess impurity clearance across downstream mAb process steps\n~ Interpret residual DNA data generated from complex\, protein-rich matrices to support process decision-making\n~ Identify key performance characteristics (e.g.\, sensitivity\, recovery\, reproducibility) required for validation-ready residual DNA assays\n~ Apply strategies for designing residual DNA workflows that remain robust and scalable from development through manufacturing
URL:https://thebiocalendar.com/event/using-residual-dna-quantification-data-to-de-risk-mab-development/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-11-26-Thermo-Reg-1920x250-0.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T160000
DTEND;TZID=America/New_York:20260611T183000
DTSTAMP:20260607T231421
CREATED:20260507T161956Z
LAST-MODIFIED:20260522T082334Z
UID:10397-1781193600-1781202600@thebiocalendar.com
SUMMARY:BVS\, in collaboration with JLL: Biotech Community Innovation Night at 115 Munson\, New Haven
DESCRIPTION:We are very excited to invite you to our BVS\, in collaboration with JLL Biotech Community Innovation Night at 115 Munson! \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe are inviting all research scientists from the institutes\, biotech and other companies in New Haven and surrounding areas to attend this event. \n✨ What to Expect: \nVendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\nNetworking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\nBuilding Tours: Building tours of available space are available upon request.\nDelicious Food & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits. \nAdmission Details: \n– FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions\,etc.) from life science companies and research institutes.\n– $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there!
URL:https://thebiocalendar.com/event/bvs-biotech-community-innovation-night-at-115-munson-new-haven-4/
CATEGORIES:Expo,Trade Show
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/05/BVS-Biotech-Event-Flyer-06-11-26.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260614
DTEND;VALUE=DATE:20260619
DTSTAMP:20260607T231421
CREATED:20260316T091256Z
LAST-MODIFIED:20260316T091256Z
UID:10024-1781395200-1781827199@thebiocalendar.com
SUMMARY:DIA 2026 Global Annual Meeting
DESCRIPTION:The DIA Global Annual Meeting is where life sciences professionals from industry\, regulatory agencies\, patients\, and academia come together to drive breakthroughs in healthcare — advancing science\, policy\, and patient outcomes worldwide.
URL:https://thebiocalendar.com/event/dia-2026-global-annual-meeting/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Annual Meeting
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260615T110000
DTEND;TZID=America/Los_Angeles:20260615T120000
DTSTAMP:20260607T231421
CREATED:20260519T190644Z
LAST-MODIFIED:20260522T082236Z
UID:10473-1781521200-1781524800@thebiocalendar.com
SUMMARY:Solving Formulation Challenges Across Modalities: Patient-Centric Nanoparticle Approaches for Small and Large Molecules
DESCRIPTION:Explore how advanced nanoparticle engineering is transforming formulation across both small and large molecule modalities. Dr. Chris Worrall highlights how Nanoform’s technologies enable higher drug‑loading oral tablets\, ultra‑high‑concentration biologic formulations for SubQ delivery\, and new possibilities for pulmonary administration. Through real case studies\, you’ll see how nanoforming can reduce pill burden\, unlock patient‑friendly alternatives to IV infusion\, and improve therapeutic performance across modalities. \nKey learning objectives:\n– Overview of Nanoform’s Innovative Small and Large Molecule Nanoforming Technology Platforms to enable patient centric dosage forms\n– Case studies showcasing reduction in pill size and overall pill burden whilst maintaining exposure of supersaturating ASDs\n– A review of alternative dosage forms to IV infusions for large molecule therapeutics
URL:https://thebiocalendar.com/event/solving-formulation-challenges-across-modalities-patient-centric-nanoparticle-approaches-for-small-and-large-molecules/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-15-26-Nanoform-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260616T110000
DTEND;TZID=America/Los_Angeles:20260616T120000
DTSTAMP:20260607T231421
CREATED:20260519T191458Z
LAST-MODIFIED:20260522T082159Z
UID:10481-1781607600-1781611200@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update June 2026:   Cell Therapy
DESCRIPTION:In this session\, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing\, scale-up\, and commercial readiness—and where different approaches can reduce downstream risk or introduce it. \nThis is a focused look at who does what\, and where they fit—so you can evaluate partners with greater clarity and move forward with more confidence.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-cell-therapy/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-CELL-THERAPY-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260616T110000
DTEND;TZID=America/Los_Angeles:20260616T120000
DTSTAMP:20260607T231421
CREATED:20260528T173411Z
LAST-MODIFIED:20260528T173411Z
UID:10549-1781607600-1781611200@thebiocalendar.com
SUMMARY:The Levers And Tradeoffs That Drive Process Productivity
DESCRIPTION:Increasing titers isn’t the only way to maximize process efficiency. Whether you’re optimizing an existing process or developing the next generation of biologics\, we can help you identify the levers that matter most. \nJoin us for an interactive discussion on the process decisions\, tradeoffs\, and operational realities shaping modern biologics manufacturing. Bioprocess Online’s Tyler Menichiello will moderate a conversation with two industry experts bringing firsthand experience in process development and biopharmaceutical manufacturing: \n• David Scherr\, Ph.D.\, Senior Scientist\, Bioprocessing Technologies and Engineering at AstraZeneca\n• Vadim Klyushnichenko\, Ph.D.\, VP\, Biopharmaceutical Development and Quality at Calibr-Skaggs Institute for Innovative Medicines \nScherr and Klyushnichenko will discuss where productivity gains are actually achieved and how teams are finding success by simplifying purification strategies and reducing chromatography steps. They will also explore how less obvious constraints (e.g.\, developability and facility fit) can shape productivity early and how complex molecules like bispecifics are redefining what process efficiency looks like. \nReserve your spot today.
URL:https://thebiocalendar.com/event/the-levers-and-tradeoffs-that-drive-process-productivity/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/26_06-BPOL-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260616T130000
DTEND;TZID=America/Los_Angeles:20260616T140000
DTSTAMP:20260607T231421
CREATED:20260519T191645Z
LAST-MODIFIED:20260522T082135Z
UID:10485-1781614800-1781618400@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update June 2026: Cell Line Development
DESCRIPTION:In this session\, leading CDMO experts will break down the key decisions across host cell selection\, vector design\, and clone screening strategies\, and explain how those choices impact expression\, scalability\, and long-term manufacturability. \nThese presentations will highlight how different CDMO approaches can reduce downstream risk or introduce it\, as programs move from early development into tech transfer and commercial readiness. \nIf you are advancing a monoclonal antibody\, recombinant protein\, or next-generation biologic\, this session will help clarify what to evaluate early—and what to avoid.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-cell-line-development/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-cell-line-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260617T100000
DTEND;TZID=America/Los_Angeles:20260617T170000
DTSTAMP:20260607T231421
CREATED:20260501T115107Z
LAST-MODIFIED:20260501T115107Z
UID:10320-1781690400-1781715600@thebiocalendar.com
SUMMARY:Bay Area Life Sciences & Biotech Conference
DESCRIPTION:What You’ll Learn: \n\nGain insights into how renewed leasing activity\, selective capital and improving absorption are reshaping demand\, investment\, and development decisions across the Bay Area life sciences market.\nLearn how owners\, developers\, and operators are rethinking space utilization\, right sizing portfolios\, and repositioning existing assets to meet today’s tenant expectations.\nExamine why South San Francisco and the Peninsula continue to anchor regional growth and how emerging submarkets are positioning themselves to compete for talent and capital.\nGain insights into how architects\, engineers\, and builders are designing flexible\, scalable\, and technology enabled lab environments that can adapt to evolving research and operational needs.\nLearn how universities\, incubators\, and corporate partners are strengthening commercialization pipelines and supporting the next generation of biotech companies.\nGain insight into how AI\, automation\, and data analytics are transforming research workflows\, space management\, and building performance.\nHear the latest strategies for delivering sustainable\, electrified\, and high-performing lab facilities while balancing cost\, compliance\, and long-term value.\n\nHow You’ll Do More Business: After several years of market recalibration\, the Bay Area life sciences sector is entering a new phase defined by selective capital deployment\, shifting demand and location preferences\, and a renewed focus on high-quality\, future-ready assets. Join our full-day conference to hear from and connect with the region’s leading life sciences decision-makers\, capital partners\, developers\, and innovators. You’ll gain the insights\, relationships\, and deal-making opportunities needed to position your business for growth in the next chapter of the Bay Area life sciences market. \nWho You’ll Meet During Networking: Owners\, developers\, investors\, biotech tenants\, brokers\, city and government officials\, business consultants\, architects\, engineers\, lawyers\, accountants\, and bankers. \nWhy You Should Attend This Session: Bisnow events bring together the biggest power players in the industry to help you identify opportunities\, build your network\, and expand your business. With the largest audience of commercial real estate professionals in the world\, no one knows how to help your business more than we do.
URL:https://thebiocalendar.com/event/bay-area-life-sciences-biotech-conference/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Forum,Networking
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260617T110000
DTEND;TZID=America/Los_Angeles:20260617T120000
DTSTAMP:20260607T231421
CREATED:20260519T124820Z
LAST-MODIFIED:20260522T082112Z
UID:10453-1781694000-1781697600@thebiocalendar.com
SUMMARY:The True Science Behind eCOA\, Shaped By Patient and Site Insights
DESCRIPTION:Clinical trials sit at a unique intersection of science\, patients\, and clinical care\, and for decades\, the “gold standard” has prioritized the rigor of the data\, often at the expense of the patients providing it. This gap between rigid protocol requirements and the realities of patients’ lives is a primary driver of participant hesitancy and high dropout rates. In eCOA\, where patient and site contributions are foundational to data quality\, this tension is especially consequential. Visit frequency\, required tasks\, and device flexibility all shape patient burden\, and these on-the-ground realities are too often absent from protocol design. \nThis webinar brings together patients\, sites\, and eCOA science to dismantle the researcher-subject hierarchy and replace it with a collaborative model. Through a panel discussion\, we’ll translate these perspectives into practical\, real-world insights to guide decisions within your protocol. This session aims to offer a more grounded blueprint for scientifically sound protocol design\, one where patient and site insights are embedded in the DNA of your eCOA strategy. \nKey Themes: \nThe Burden of Participation: Moving from “What data do we need?” to “How will this protocol impact a Tuesday afternoon for a single parent or a working professional?” and what trial design choices around eCOA follow from that shift. \nThe Site Lens: What sites observe firsthand when poor trial design translates to patient burden and operational friction \nTechnology as an Equalizer: How digital tools can reduce participation burden and improve data capture without creating a digital divide that excludes non-tech-savvy participants. \nDefining eCOA Science: What do we even mean by eCOA science? What might different stakeholders be thinking of with this term? And how does it differ from COA science?
URL:https://thebiocalendar.com/event/the-true-science-behind-ecoa-shaped-by-patient-and-site-insights/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-17-26-Medidata-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260617T110000
DTEND;TZID=America/Los_Angeles:20260617T120000
DTSTAMP:20260607T231421
CREATED:20260519T191814Z
LAST-MODIFIED:20260522T082045Z
UID:10489-1781694000-1781697600@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update June 2026: Microbial Development & Manufacturing
DESCRIPTION:Join us for this digital event designed for pharmaceutical and biopharmaceutical companies seeking reliable CDMO partnerships to accelerate their microbial programs from development through commercial manufacturing. By attending this digital event\, you will learn how these capabilities come together to support efficient development\, smooth scale-up\, and consistent production. \nThe presentations will also provide insight into how experienced partners streamline timelines\, reduce risk\, and address the regulatory and quality considerations critical to successful program execution. \nWhether you are advancing early-stage research or preparing for commercial manufacturing\, you will gain practical guidance to help select a CDMO aligned with your technical\, quality\, and supply chain requirements.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-microbial-development-manufacturing/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-MICROBIAL-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260617T130000
DTEND;TZID=America/Los_Angeles:20260617T140000
DTSTAMP:20260607T231421
CREATED:20260519T191928Z
LAST-MODIFIED:20260522T082024Z
UID:10493-1781701200-1781704800@thebiocalendar.com
SUMMARY:Outsourced Pharma Capabilities Update June 2026: Antibody Drug Conjugates
DESCRIPTION:In this Capabilities Update\, CDMOs will share how they support ADC programs from early development through clinical and commercial manufacturing. By attending this digital event\, you will gain insight into the technical expertise\, scalability\, and regulatory considerations required to advance ADCs efficiently. \nThe presentations will also highlight key considerations when evaluating CDMO partners\, including experience with complex conjugation processes and the ability to deliver integrated development and manufacturing support. \nWhether you are initiating a new ADC program or refining existing processes\, this session provides a clearer understanding of how to select a partner aligned with your program’s technical and operational needs.
URL:https://thebiocalendar.com/event/outsourced-pharma-capabilities-update-june-2026-antibody-drug-conjugates/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-OPCU-1280x720-ADCs-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260618T110000
DTEND;TZID=America/Los_Angeles:20260618T120000
DTSTAMP:20260607T231421
CREATED:20260515T203642Z
LAST-MODIFIED:20260526T212757Z
UID:10445-1781780400-1781784000@thebiocalendar.com
SUMMARY:When Art Meets Science: Creative Chromatography Solutions for Complex Small Molecules
DESCRIPTION:Difficult to purify small molecules pose a big challenge for drug developers. Working with a CDMO that has specialized expertise in chromatography ensures that no matter the purification challenges or scale\, your program can be taken care of. Learn more…
URL:https://thebiocalendar.com/event/when-art-meets-science-creative-chromatography-solutions-for-complex-small-molecules/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-18-26-MilliporeSigma-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260618T110000
DTEND;TZID=America/Los_Angeles:20260618T120000
DTSTAMP:20260607T231421
CREATED:20260519T130313Z
LAST-MODIFIED:20260522T082002Z
UID:10457-1781780400-1781784000@thebiocalendar.com
SUMMARY:Breaking the CLD Bottleneck: Generate Stable High-Producing Clones in 14 Weeks
DESCRIPTION:Given its inherent time and resource demands\, variability in productivity\, and the rising complexity of monoclonal antibody (mAb) modalities—including bispecific antibodies (bsAb) and fusion proteins—cell line development (CLD) has become a leading constraint on bioprocess development. \nDesigned to address these constraints\, the Gibo™ CHOvantage™ GS CLD kit is a transposon-based CHO-K1 CLD platform that offers a solution for the accelerated production of stable\, high-performing cell lines. Using this platform\, mAb\, bsAb\, and Fc-fusion protein cell lines were generated in less than 14 weeks with high-titer pools consistently producing up to 5 g/L and corresponding stable clone titers reaching greater than 7 g/L. Selected clones were successfully scaled to bench scale and found to be stable in production and product quality for up to 100 generations. Collectively\, this demonstrates that the CHOvantage™ platform enables rapid\, robust\, and scalable generation of high-producing cell lines and represents an effective solution for accelerating biotherapeutic development.
URL:https://thebiocalendar.com/event/breaking-the-cld-bottleneck-generate-stable-high-producing-clones-in-14-weeks/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-18-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260618T130000
DTEND;TZID=America/Los_Angeles:20260618T190000
DTSTAMP:20260607T231421
CREATED:20260513T134910Z
LAST-MODIFIED:20260513T134910Z
UID:10443-1781787600-1781809200@thebiocalendar.com
SUMMARY:Bases & Breakthroughs
DESCRIPTION:A summer outing that actually does something. \nBases & Breakthroughs is built for teams. It’s an easy\, high-energy way for life science companies and supporters to invest in Philadelphia while giving employees\, clients\, partners\, and colleagues a memorable night out at the ballpark. \nYour ticket includes access to our pregame hospitality experience at Citizens Bank Park with ballpark eats and drinks\, plus seats together in our dedicated Life Science Cares section for Phillies vs. Mets. It’s casual\, social\, and designed for the region’s life sciences community to show up together.
URL:https://thebiocalendar.com/event/bases-breakthroughs/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Social
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260621
DTEND;VALUE=DATE:20260622
DTSTAMP:20260607T231421
CREATED:20260501T115213Z
LAST-MODIFIED:20260501T115213Z
UID:10321-1782000000-1782086399@thebiocalendar.com
SUMMARY:2026 SoCal TBA 10th Anniversary Symposium: AI\, Biotech & VC at UCLA
DESCRIPTION:Celebrate 10 years of biotech innovation at UCLA. Explore the future of AI in medicine with VCs\, founders\, and industry leaders. \n\n\n\n\nFor the past decade\, SoCal TBA has connected the biotech communities of Southern California and Taiwan. This year’s theme\, “From Foundations to Frontiers: AI\, Innovation\, and the Future of Biomedicine\,” brings together leaders in venture capital\, biotech startups\, academia\, and industry to explore how AI is transforming the future of medicine. \nWhether you are a founder\, investor\, scientist\, student\, or biotech professional\, this symposium is designed to help you build relationships\, discover new ideas\, and stay ahead of where the industry is going next.
URL:https://thebiocalendar.com/event/2026-socal-tba-10th-anniversary-symposium-ai-biotech-vc-at-ucla/
LOCATION:Los Angeles\, Los Angeles\, CA\, United States
CATEGORIES:Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260622
DTEND;VALUE=DATE:20260626
DTSTAMP:20260607T231421
CREATED:20251121T160254Z
LAST-MODIFIED:20251121T160254Z
UID:9564-1782086400-1782431999@thebiocalendar.com
SUMMARY:BIO 2026
DESCRIPTION:The industry’s premier event hosts thousands from across the global biotech ecosystem. Four days of programming\, networking\, Company Presentations\, and BIO Partnering™ focus on the future of our industry and make this a must-attend event. \n\n\n\n\n\n\nBIO 2026 is where we return to this essential “why.” It is our opportunity to reconnect as a global community\, to recharge our commitment\, and to remember that behind every innovation is a shared mission: to improve lives.
URL:https://thebiocalendar.com/event/bio-2026/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Investor,Networking,Partnering,Summit,Trade Show
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260622T110000
DTEND;TZID=America/Los_Angeles:20260622T120000
DTSTAMP:20260607T231421
CREATED:20260521T162343Z
LAST-MODIFIED:20260522T081936Z
UID:10504-1782126000-1782129600@thebiocalendar.com
SUMMARY:From Variable to Predictable: How Intensified Upstream Processing Improves Scale-Up and Tech Transfer
DESCRIPTION:As biomanufacturers face increasing pressure to boost productivity\, reduce costs\, and accelerate timelines\, traditional scale-up approaches can introduce variability and performance drift. Intensified upstream processing offers a more scalable\, efficient path forward—helping maintain product quality\, process stability\, and regulatory compliance from development through GMP manufacturing. \nIn this webinar\, Thermo Fisher Scientific experts share best practices and real-world insights on implementing intensified upstream strategies\, supported by advanced automation\, process analytical technologies (PAT)\, and data-driven control. \nIn this session\, you will learn how to:\n~ Drive productivity with intensification strategies\n~ Accelerate timelines using high-density inoculation and optimized seed trains\n~ Increase output through perfusion and hybrid processing models\n~ Improve consistency with automation\, PAT\, and real-time control\n~ Enable reliable scale-up with standardized tech transfer approaches \nKey challenges addressed:\n~ Performance drift and variability during scale-up\n~ Limited productivity with traditional processes\n~ Long development and seed train timelines\n~ Inconsistent results across sites \nDiscover how intensified upstream processing can help you scale with confidence while improving efficiency\, consistency\, and speed across your operations.
URL:https://thebiocalendar.com/event/from-variable-to-predictable-how-intensified-upstream-processing-improves-scale-up-and-tech-transfer/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-22-26-Thermo-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260622T110000
DTEND;TZID=America/Los_Angeles:20260622T120000
DTSTAMP:20260607T231421
CREATED:20260528T121901Z
LAST-MODIFIED:20260528T121901Z
UID:10536-1782126000-1782129600@thebiocalendar.com
SUMMARY:Driving Faster Clinical Trial Setup: How Humans and AI Collaborate to Improve Quality\, Speed\, and Agility in Study Build
DESCRIPTION:Study build inefficiency is rarely caused by a single failure point. Instead\, delays accumulate across fragmented protocol interpretation\, manual configuration\, iterative amendments\, and validation cycles that often surface issues late—when they are more costly to resolve. For many sponsors and CROs\, this has become the accepted baseline. The more important question is whether it needs to be. \nThis webinar explores how a more integrated human–AI collaboration model can address these challenges. Drawing on practical experience from study build environments\, we examine how AI can be applied not just to automate individual tasks\, but to support the full lifecycle—from protocol interpretation through configuration and validation. In this model\, AI contributes context-aware support grounded in clinical data structures and study design logic\, while clinical and operational experts guide decisions\, validate outputs\, and ensure regulatory alignment. \nWe will share how this approach is being implemented in practice\, including where AI can help reduce rework\, improve consistency in configuration\, and surface potential downstream issues earlier in the process. Particular focus will be given to how teams are balancing increased speed with the need for control\, auditability\, and quality. \nThrough real-world examples and live demonstration segments\, attendees will gain a practical understanding of how human expertise and AI can work together to improve study build performance—enabling faster timelines while maintaining rigor. \nWhy attend:\n– Gain a realistic\, experience-based perspective on AI in clinical operations\n– See how these approaches are being applied within active study environments\n– Understand how to improve speed without compromising quality or oversight
URL:https://thebiocalendar.com/event/driving-faster-clinical-trial-setup-how-humans-and-ai-collaborate-to-improve-quality-speed-and-agility-in-study-build/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-22-26-Endpoint-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260622T130000
DTEND;TZID=America/Los_Angeles:20260622T150000
DTSTAMP:20260607T231421
CREATED:20260507T200048Z
LAST-MODIFIED:20260507T200048Z
UID:10403-1782133200-1782140400@thebiocalendar.com
SUMMARY:Venture Hub Showcase: International Pitch Event at BIO 2026
DESCRIPTION:Biocom is pleased to announce our upcoming Venture Hub Showcase—an international pitch event taking place during the 2026 BIO International Convention. This event offers a valuable opportunity to connect with potential strategic partners and investors\, while exploring the latest life science innovations from fellow industry leaders. Light snacks and refreshments will be provided.
URL:https://thebiocalendar.com/event/venture-hub-showcase-international-pitch-event-at-bio-2026/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Presentation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260623T100000
DTEND;TZID=America/Los_Angeles:20260623T140000
DTSTAMP:20260607T231421
CREATED:20260511T125601Z
LAST-MODIFIED:20260522T081902Z
UID:10405-1782208800-1782223200@thebiocalendar.com
SUMMARY:Bio-Expo Live: Upstream Bioprocessing
DESCRIPTION:Bioprocess Online’s Bio-Expo Live is back with its series of live virtual events designed to empower biopharma professionals. Through these sessions\, attendees will have the chance to explore the newest equipment and solutions offered by our presenters\, aimed at addressing the current challenges within the drug development process. This interactive online platform ensures convenience and accessibility\, fostering an environment of learning and innovation for all participants. \nThe attendees of the Upstream Manufacturing session will have the chance to explore the newest equipment and solutions offered by our presenting suppliers essential to therapeutic areas from ADCs to vaccines. \nWhat can you expect? Short\, digital presentations with live interaction. You will have the opportunity to ask questions to better understand if they can meet your needs – all from the convenience of your computer! \nPlease note that this event is for biopharma companies or contract manufacturers seeking available products/solutions to help them overcome upstream manufacturing challenges.
URL:https://thebiocalendar.com/event/bio-expo-live-upstream-bioprocessing-4/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-BEL-1280x720-upstream-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260623T110000
DTEND;TZID=America/Los_Angeles:20260623T120000
DTSTAMP:20260607T231421
CREATED:20260519T145520Z
LAST-MODIFIED:20260522T081837Z
UID:10461-1782212400-1782216000@thebiocalendar.com
SUMMARY:Mastering Inspection: Strategies to Reduce Downtime and Ensure Quality
DESCRIPTION:This webinar explores why inspection in HMLV environments is inherently challenging and identifies the most common pain points faced by operations\, engineering\, and quality teams.
URL:https://thebiocalendar.com/event/mastering-inspection-strategies-to-reduce-downtime-and-ensure-quality/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-23-26-Koerber-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260623T130000
DTEND;TZID=America/Los_Angeles:20260623T140000
DTSTAMP:20260607T231421
CREATED:20260526T130313Z
LAST-MODIFIED:20260526T130313Z
UID:10508-1782219600-1782223200@thebiocalendar.com
SUMMARY:Automating cell therapy manufacturing without redesigning established workflows
DESCRIPTION:As cell therapy programs transition into clinical development\, manufacturing teams face increasing pressure to automate workflows while preserving biological performance and hard-earned process knowledge. Many teams hesitate to introduce automation due to concerns around forced process redesign\, loss of flexibility\, or risks to clinical timelines. \nIn this webinar\, Cytiva specialists will demonstrate how the Sefia™ cell therapy manufacturing platform enables closed\, automated processing without requiring changes to existing media\, reagents\, or core process logic. Using real workflow learnings and development examples\, the speakers will explore how automation can be introduced incrementally to support clinical readiness today while preparing for future scale. \nAttendees will gain practical guidance on mapping their current workflows to an automation-ready platform\, reducing operational risk\, and building a clear path from development to GMP manufacturing. \nKey learning objectives: \n    Understand how to automate cell therapy workflows without redesigning biology\n    Identify platform features that support clinical readiness and future scale\n    Learn how closed\, modular systems reduce operational risk while preserving flexibility
URL:https://thebiocalendar.com/event/automating-cell-therapy-manufacturing-without-redesigning-established-workflows/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260623T203000
DTEND;TZID=America/Los_Angeles:20260623T233000
DTSTAMP:20260607T231421
CREATED:20260507T200213Z
LAST-MODIFIED:20260508T105803Z
UID:10404-1782246600-1782257400@thebiocalendar.com
SUMMARY:Golden Hour | Biocom Reception at #BIO2026
DESCRIPTION:During the 2026 BIO International Convention\, join Biocom for its highly anticipated Member-Only Bash in partnership with IQHQ—an unforgettable evening bringing together the global life science community. \nThis highly anticipated event brings together professionals from around the world for a dynamic evening of networking\, collaboration\, and celebration. Set against a stunning waterfront backdrop\, Biocom’s BIO Bash offers a unique opportunity to connect with industry leaders\, exchange ideas\, and engage with innovators shaping the future of life sciences. \nEvent Highlights \n\nGlobal audience of life science leaders and innovators\nHigh-impact networking in a vibrant\, social setting\nUnique waterfront venue experience\nCelebration of innovation and industry achievements\n\nMark your calendar for an evening filled with energy\, connection\, and collaboration—an essential gathering during one of the industry’s most influential weeks.
URL:https://thebiocalendar.com/event/golden-hour-biocom-reception-at-bio2026/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Social
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260624T100000
DTEND;TZID=America/Los_Angeles:20260624T140000
DTSTAMP:20260607T231421
CREATED:20260511T125831Z
LAST-MODIFIED:20260522T081810Z
UID:10409-1782295200-1782309600@thebiocalendar.com
SUMMARY:Bio-Expo Live: Downstream Bioprocessing
DESCRIPTION:During the 2026 BIO International Convention\, join Biocom for its highly anticipated Member-Only Bash in partnership with IQHQ—an unforgettable evening bringing together the global life science community. \nThis highly anticipated event brings together professionals from around the world for a dynamic evening of networking\, collaboration\, and celebration. Set against a stunning waterfront backdrop\, Biocom’s BIO Bash offers a unique opportunity to connect with industry leaders\, exchange ideas\, and engage with innovators shaping the future of life sciences. \nEvent Highlights \n\nGlobal audience of life science leaders and innovators\nHigh-impact networking in a vibrant\, social setting\nUnique waterfront venue experience\nCelebration of innovation and industry achievements\n\nMark your calendar for an evening filled with energy\, connection\, and collaboration—an essential gathering during one of the industry’s most influential weeks.
URL:https://thebiocalendar.com/event/bio-expo-live-downstream-bioprocessing-3/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-BEL-1280x720-downstream-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260624T110000
DTEND;TZID=America/Los_Angeles:20260624T120000
DTSTAMP:20260607T231421
CREATED:20260528T121712Z
LAST-MODIFIED:20260528T121712Z
UID:10532-1782298800-1782302400@thebiocalendar.com
SUMMARY:Global Regulatory Compliance for Aseptic Barrier Systems
DESCRIPTION:As sterile pharmaceutical manufacturing evolves\, isolators and Restricted Access Barrier Systems (RABS) have become central to contamination control strategies across global markets. Yet regulatory expectations from the FDA\, EU GMP Annex 1\, PIC/S\, and WHO differ in meaningful ways\, from legal enforceability to technical prescriptiveness\, creating compliance complexity for manufacturers supplying multiple markets. \nThis webinar provides a structured comparison of the four major regulatory frameworks governing aseptic barrier systems\, examining where they converge on scientific fundamentals and where they diverge in documentation requirements\, monitoring expectations\, and treatment of advanced technologies. Special focus will be given to the 2022 revision of EU GMP Annex 1 and its harmonized adoption across PIC/S and WHO. \nAttendees will leave with a clearer understanding of how to design and qualify barrier systems that satisfy both the principle-based flexibility of the FDA and the structured minimum standards of the EU/PIC/S/WHO model\, supporting a robust\, globally acceptable contamination control strategy. \nKEY LEARNING OBJECTIVES \n– Understand how FDA\, EU GMP Annex 1\, PIC/S\, and WHO align and differ in their requirements for isolators\, RABS\, and contamination control strategy documentation\n– Identify the practical compliance implications of regulatory divergence for manufacturers operating across multiple jurisdictions\n– Apply a risk-based framework for barrier system design\, decontamination validation\, and environmental monitoring that satisfies global inspection expectations
URL:https://thebiocalendar.com/event/global-regulatory-compliance-for-aseptic-barrier-systems/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-24-26-Esco-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260625T100000
DTEND;TZID=America/Los_Angeles:20260625T140000
DTSTAMP:20260607T231421
CREATED:20260511T130147Z
LAST-MODIFIED:20260522T081737Z
UID:10413-1782381600-1782396000@thebiocalendar.com
SUMMARY:Bio-Expo Live: Bioprocess Quality\, Data\, & Analytical Solutions
DESCRIPTION:Bioprocess Online’s Bio-Expo Live is back with its series of live virtual events designed to empower biopharma professionals. Through these sessions\, attendees will have the chance to explore the newest equipment and solutions offered by our presenters\, aimed at addressing the current challenges within the drug development process. This interactive online platform ensures convenience and accessibility\, fostering an environment of learning and innovation for all participants. \nThe attendees of the Data\, Quality\, & Analytical session will have the chance to explore the latest equipment and solutions offered by our presenting suppliers essential to biopharmaceutical development and manufacturing. \nWhat can you expect? Short\, digital presentations with live interaction. You will have the opportunity to ask questions to better understand if they can meet your needs – all from the convenience of your computer! \nPlease note that this event is for biopharma companies or contract manufacturers seeking available quality\, data\, and/or analytical products/solutions to help them overcome their manufacturing challenges.
URL:https://thebiocalendar.com/event/bio-expo-live-bioprocess-quality-data-analytical-solutions-3/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-2026-BEL-1280x720-BQDA-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260625T110000
DTEND;TZID=America/Los_Angeles:20260625T120000
DTSTAMP:20260607T231421
CREATED:20260526T130939Z
LAST-MODIFIED:20260526T212741Z
UID:10516-1782385200-1782388800@thebiocalendar.com
SUMMARY:False Rejects Aren’t Inevitable: How to Reduce Waste and Improve Line Efficiency
DESCRIPTION:False rejects are more than a nuisance—they create unnecessary waste\, disrupt production efficiency\, and erode confidence in inspection systems. \nIn this webinar\, we will explore the top 10 causes of false rejects across system setup\, environmental conditions\, and product and operational variability. We will also demonstrate why false rejects are not inevitable\, but instead indicators of correctable issues. \nAttendees will gain insight into how false rejects may affect yield\, throughput\, compliance\, and brand reputation. We’ll also explore a range of practical considerations that can help minimize false rejects\, including system setup\, environmental conditions\, and day-to-day operational practices. \nThe webinar will conclude with a simple\, actionable checklist to help teams drive consistent\, reliable performance on the production line. \nKey Learning Objectives: \nIdentify the most common causes of false rejects and their impact on efficiency\, quality\, and compliance\nApply practical strategies to stabilize systems\, control environmental factors\, and reduce variability\nImplement a structured approach and checklist to systematically reduce false rejects and improve line performance
URL:https://thebiocalendar.com/event/false-rejects-arent-inevitable-how-to-reduce-waste-and-improve-line-efficiency/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-25-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
END:VCALENDAR